# PSIL (AdvisorShares Psychedelics ETF)

AdvisorShares · Thematic ETFs · data as of Sep 11, 2026

PSIL holds 27 stocks, and 92% of its weight is outside the S&P 500.

## Key facts

- PSIL, already in the S&P 500: 8.1%, as of Sep 11, 2026.
- PSIL, active share vs the S&P 500: 98.4%, as of Sep 11, 2026.
- PSIL, top ten holdings: 72.2%, as of Sep 11, 2026.
- PSIL, total return, 1 year: +51.5%, as of Sep 11, 2026.
- PSIL, net assets: $44m (SEC filing, whole fund, as filed for Jun 30, 2026).
- PSIL, expense ratio: 1.00% (485BPOS XBRL, Oct 28, 2025).

## PSIL over each window to Sep 11, 2026

| Window | Total return | S&P 500 | Gap to S&P 500 | Gap to Nasdaq-100 |
| --- | --- | --- | --- | --- |
| 3 months | +22.9% | +3.3% | +19.6 pts | +23.6 pts |
| 6 months | +49.0% | +16.0% | +32.9 pts | +28.3 pts |
| 1 year | +51.5% | +17.5% | +34.0 pts | +28.5 pts |
| 3 years | +61.5% | +77.9% | −16.3 pts | −33.5 pts |
| Since launch | −71.2% | +82.9% | −154.1 pts | −165.9 pts |

## Every published field

| Field | Value | Source |
| --- | --- | --- |
| Theme | Therapeutics and medical devices | ETFIQ, editorial |
| Launched | Sep 16, 2021 | ETFIQ |
| Already in the S&P 500, by weight | 8.1% | ETFIQ |
| Active share vs the S&P 500 | 98.4% | ETFIQ |
| Already in the Nasdaq-100, by weight | 0.0% | ETFIQ |
| Active share vs the Nasdaq-100 | 100.0% | ETFIQ |
| Top ten holdings weight | 72.2% | ETFIQ |
| Holdings | 27 | ETFIQ |
| Holdings as of | Jun 30, 2026 | SEC N-PORT |
| Top holdings | DEFINIUM THERAPEUTICS INC 13.4%, COMPASS PATHWAYS PLC 11.9%, ATAIBECKLEY INC 10.9%, RELMADA THERAPEUTICS INC 7.1%, NRX PHARMACEUTICALS INC 6.3%, NEUROCRINE BIOSCIENCES INC 4.6%, CYBIN INC 4.5%, GH RESEARCH PLC 4.5%, ALKERMES PLC 4.5%, ALTO NEUROSCIENCE INC 4.4% | ETFIQ |
| Net assets | $44m | SEC filing, whole fund, as filed for Jun 30, 2026 |
| Below its all-time high | −72.0% | ETFIQ |
| Expense ratio | 1.00% | 485BPOS XBRL, Oct 28, 2025 |
| Fee for the part that differs from the S&P 500, active expense ratio | 1.02% | ETFIQ |
| Closest funds by holdings overlap | IBRN 12%, BMED 10% | ETFIQ |

## Questions

### How much of PSIL is in S&P 500 companies?

By its holdings filed for Jun 30, 2026, 8% of PSIL by weight is stocks the S&P 500 already holds. Its active share against the index is 98%, so that share is the part doing something different.

### What does PSIL hold?

27 positions as filed for Jun 30, 2026, with the top ten at 72% of the fund. The largest are DEFINIUM THERAPEUTICS INC at 13.4%, COMPASS PATHWAYS PLC at 11.9%, ATAIBECKLEY INC at 10.9%.

### Has PSIL beaten the S&P 500?

Over the year to Sep 11, 2026 PSIL returned +51.5% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 34.0 points.

### What does PSIL cost?

The prospectus expense ratio is 1.00% a year. Because 98% of the fund differs from the S&P 500, the fee on that differing part works out at 1.02%.


## Cite this page

ETFIQ, PSIL, data as of Sep 11, 2026. https://etfiq.com/funds/PSIL
Free to use with attribution; the underlying files are at https://etfiq.com/data/.

HTML: https://etfiq.com/funds/PSIL  ·  JSON: https://etfiq.com/funds/PSIL.json